13.20: Documentation Requirements and Oversight

Quality and Regulatory Compliance in Bioscience · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY-SA 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    13.20: Documentation Requirements and Oversight

    For finished pharmaceuticals, review the applicable sections of 21 CFR Part 211, including 211.180, 211.182, 211.186, 211.188, 211.192, and 211.194. GLP, clinical research, biological products, and devices have additional or different requirements. Always check the scope of a requirement before applying it to a new setting.

    FDA may issue Form FDA 483 to communicate inspectional observations. It is not a final agency determination of compliance. A warning letter is a separate action and does not automatically follow every Form 483. Missing, unreliable, or falsified records can be significant findings that require prompt investigation and appropriate corrective action.

    ISO 9001 also requires suitable documented information for the QMS and evidence of its operation. The required detail depends on the organization and applicable requirements. ISO 9001 certification concerns the defined management system scope; it is not laboratory accreditation or FDA approval. ISO currently lists ISO 9001:2026. Historical quotations from ISO 9001:2008 should not be presented as the current requirements.

    Documentation_ Check the Requirement.png


    This page titled 13.20: Documentation Requirements and Oversight was last modified on Sun, 08 Nov 2026 21:55:12 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.